# *Corrigendum*

Journal of Applied Pharmaceutical Science
Available online at http://www.japsonline.com
Vol. 15(05), pp. 254-256, May, 2025
DOI: 10.7324/JAPS.2025.110307.corrigendum
Published: April 05, 2025

## Corrigendum to "*De novo* designed lactoferrin–oleic acid-loaded chitosan nanoparticles with improved activity and selectivity toward four human cancer cells as compared to conventional complexes"

The article titled '*De novo* designed lactoferrin–oleic acid-loaded chitosan nanoparticles with improved activity and selectivity toward four human cancer cells as compared to conventional complexes' was published in volume 11, issue 03 of the Journal of Applied Pharmaceutical Science [1].

In the original publication, unintentional errors occurred in Figures 2 and 6 due to the use of duplicated images. The authors have recognized this oversight and submitted corrected versions of the affected figures.

**Incorrect images:** Duplicated images in fig. 2 (image of CIII and BIV) and fig. 6 (Ki67 II, III and Bcl-2 II, III)."




**Figure 2:** Morphological alterations of HepG-2 (A), Caco-2 (B), Hela(C), and MCF-7 (D) under phase-contrast microscope with 200× magnification. (I) Untreated cells, (II) cells treated with EC100 of cLf–OA complex for 72 hours, (III) cells treated with EC100 of hLf–OA complex for 72 hours, (IV) cells treated with EC100 of cLf–OA nanocomplex for 72 hours, and (V) cells treated with EC100 of hLf–OA nanocomplex for 72 hours.




**Figure 6:** Immunocytochemistry analysis for Ki-67, Bcl-2, and p53 of HepG-2. (I) Untreated cells, (II) cells treated with cLf–OA nanocomplex, and (III) cells treated with hLf–OA nanocomplex.

**Correction:** The incorrect images are now replaced with the following revised images (BIV in fig. 2 and Bcl2 II&III in fig. 6) with the revised ones (green highlighted) as shown in the corrected fig. 2 and 6.




**Figure 2:** Morphological alterations of HepG-2 (A), Caco-2 (B), Hela(C), and MCF-7 (D) under phase-contrast microscope with 200× magnification. (I) Untreated cells, (II) cells treated with EC100 of cLf–OA complex for 72 hours, (III) cells treated with EC100 of hLf–OA complex for 72 hours, (IV) cells treated with EC100 of cLf–OA nanocomplex for 72 hours, and (V) cells treated with EC100 of hLf–OA nanocomplex for 72 hours.




**Figure 6:** Immunocytochemistry analysis for Ki-67, Bcl-2, and p53 of HepG-2. (I) Untreated cells, (II) cells treated with cLf–OA noncomplex, and (III) cells treated with hLf–OA nanocomplex.

This corrigendum corrects all previous versions of the article.

## REFERENCES

1. EL-Baky NA, Abu-Serie MM, Redwan EM. De novo designed lactoferrin–oleic acid-loaded chitosan nanoparticles with improved activity and selectivity toward four human cancer cells as compared to conventional complexes. J Appl Pharm Sci, 2021;11(03):060–070. DOI: http://dx.doi.org/10.7324/JAPS.2021.110307